PCV16 ROSUVASTATIN IS MORE COST-EFFECTIVE COMPARED TO ATORVASTATIN AND SIMVASTATIN FOR HYPERLIPIDEMIA MANAGEMENT IN HIGH-RISK PATIENTS IN ROUTINE CLINICAL PRACTICE
Abstract
Authors
RL Ohsfeldt SK Gandhi KM Fox T Stacy JM McKenney